BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35405743)

  • 21. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
    Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
    J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
    Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
    Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
    Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
    Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.
    Theruvath J; Sotillo E; Mount CW; Graef CM; Delaidelli A; Heitzeneder S; Labanieh L; Dhingra S; Leruste A; Majzner RG; Xu P; Mueller S; Yecies DW; Finetti MA; Williamson D; Johann PD; Kool M; Pfister S; Hasselblatt M; Frühwald MC; Delattre O; Surdez D; Bourdeaut F; Puget S; Zaidi S; Mitra SS; Cheshier S; Sorensen PH; Monje M; Mackall CL
    Nat Med; 2020 May; 26(5):712-719. PubMed ID: 32341579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
    Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
    J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
    Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
    Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
    Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.
    Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A
    J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
    Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
    J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity.
    Haydar D; Ibañez-Vega J; Crawford JC; Chou CH; Guy CS; Meehl M; Yi Z; Perry S; Laxton J; Cunningham T; Langfitt D; Vogel P; DeRenzo C; Gottschalk S; Roussel MF; Thomas PG; Krenciute G
    Cancer Res Commun; 2023 Dec; 3(12):2430-2446. PubMed ID: 37971169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
    Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
    Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.
    Vitanza NA; Wilson AL; Huang W; Seidel K; Brown C; Gustafson JA; Yokoyama JK; Johnson AJ; Baxter BA; Koning RW; Reid AN; Meechan M; Biery MC; Myers C; Rawlings-Rhea SD; Albert CM; Browd SR; Hauptman JS; Lee A; Ojemann JG; Berens ME; Dun MD; Foster JB; Crotty EE; Leary SES; Cole BL; Perez FA; Wright JN; Orentas RJ; Chour T; Newell EW; Whiteaker JR; Zhao L; Paulovich AG; Pinto N; Gust J; Gardner RA; Jensen MC; Park JR
    Cancer Discov; 2023 Jan; 13(1):114-131. PubMed ID: 36259971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.
    Tang X; Zhao S; Zhang Y; Wang Y; Zhang Z; Yang M; Zhu Y; Zhang G; Guo G; Tong A; Zhou L
    Mol Ther Oncolytics; 2019 Sep; 14():279-287. PubMed ID: 31485480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.
    Long C; Li G; Zhang C; Jiang T; Li Y; Duan X; Zhong G
    Front Oncol; 2021; 11():659662. PubMed ID: 34868903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer.
    Li S; Zhang M; Wang M; Wang H; Wu H; Mao L; Zhang M; Li H; Zheng J; Ma P; Wang G
    Cell Death Discov; 2023 May; 9(1):147. PubMed ID: 37149721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma.
    Tang X; Liu F; Liu Z; Cao Y; Zhang Z; Wang Y; Huang J; Fan S; Zhao S; Chen Y; Li G; Wang S; Zheng M; Hu Y; Li H; Jiang C; Yang M; Yang H; Xu J; Guo G; Tong A; Zhou L
    Clin Transl Immunology; 2020; 9(6):e1137. PubMed ID: 32547742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric Antigen Receptor T Cell with an Inducible Caspase 9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.
    Ventin M; Cattaneo G; Arya S; Jia J; Gelmi MC; Sun Y; Maggs L; Ksander BR; Verdijk RM; Boland GM; Jenkins RW; Haq R; Jager MJ; Wang X; Ryeom S; Ferrone CR
    Clin Cancer Res; 2024 May; ():. PubMed ID: 38767611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient.
    Hu G; Li G; Wen W; Ding W; Zhou Z; Zheng Y; Huang T; Ren J; Chen R; Zhu D; He R; Liang Y; Luo M
    Front Oncol; 2022; 12():956593. PubMed ID: 36059640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.